KRAS and neoplasm: However, knocking down KRAS in HCT116 (Figure 1F) and NRAS in IPC298 (Figure 1H) led to a significant delay in tumor growth, indicating the requirement of KRAS in HCT116 and NRAS in IPC298 for tumor growth in vivo.